Cost cuts are coming for Allergan, CEO Brent Saunders says

Discussion in 'Allergan' started by anonymous, Nov 3, 2017 at 5:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    Some of what you say is probably true but BS had put a lot of resources and time into Restasis. You referenced it above with the new patents he spearheaded and the new delivery system. He loves the brand and will protect it at all cost by adding head count where it makes sense.
     

  2. anonymous

    anonymous Guest

    wake up! All of this postilating is seriously a waste of your time. As with everything in life, it’s all about the money! Shareholders will demand a dramatic response to the many billions lost at AGN. The tribal debacle was the holy grail of a desperate act. The timing of the disclosure? Well, that’s the leadership here; beyond bad.
    The Bell willToll and it won’t be BS who pays; That’s you, me and everybody else.
     
  3. TeaBagAnErin

    TeaBagAnErin Guest

    Pfizer dodged a bullet when the acquisition went south.

    Looks like the traditionalists were cotreat in their skepticism towards growth pharma. All the company's that bet their existence on research and development have started growing again.

    How much will the cash payout to the board be when they sell off GI, womans health and the Botox franchise?

    The conversation has to be about selling at this point as other molecules are years away from FDA submission.
     
  4. anonymous

    anonymous Guest



    There are two big phase 3's due out in 2018. Oral migraine phase 3 1st qtr to 1st half of year, Uterine Fibroid approval sometime in 2018 and AMD phase 3 data at 3rd qtr to end of 2018. You should really get your info straight instead of spouting off with your emotional instability. That's just 2018. 2019 should see the non-ketamine depression drug as well as many others. 6 top tier drugs the industry has suggested could bring in as much as 13 billion per year.
     
  5. anonymous

    anonymous Guest

     
  6. anonymous

    anonymous Guest

    What kind of drugs are you on? The stock price has gone from over $300 a share to $175 a share. The allergan and restasis name is all over the news for all the wrong reasons.

    The Restasis patents were in place before Pyott left. The MDPF bottle was in place before Pyott left, the clinical studies and stability studies just needed to finish to get approval.

    I have zero confidence in Brent's leadership.
     
  7. anonymous

    anonymous Guest

    Maybe the hospital division still has a chance then?
     
  8. anonymous

    anonymous Guest

    Wait Saunders was instrumental in the launch and development of the Multidose bottle. That is incorrect.
     
  9. anonymous

    anonymous Guest

    exactly that bottle was in development back in late 2013 long before acquisition, when the company was acquired development was about done on that delivery system
     
  10. anonymous

    anonymous Guest


    Yep...Saunders has built the Restasis brand and expanded its footprint in his short time with the product he has worked miracles. Far more than DP ever did and more committed to the business.
     
  11. anonymous

    anonymous Guest

    While I understand this has become almost solely a sales board you all are overly focused on the implications the announced cost cutting will have on the US sales force. Allergan is a huge company with world wide capacities. While I can't suggest the US sales force won't be affected to some degree by these upcoming actions, I do suggest the "blood bath" so many fear will not occur. This division was already right-sized earlier in 2017. There may well be additional cuts, but they won't be nearly as drastic as some here may be led to believe. Around the globe there will be massive restructuring and reduction, but that will focus on big ticket research, development, manufacturing and administrative positions as well as capitol items such as facilities. In my country alone we know of 2 facilities facing closure. So, you in the US will see results from these cuts, but realize this company is much more than just you.
     
  12. anonymous

    anonymous Guest

     
  13. anonymous

    anonymous Guest

    Do the math for the layoffs. Respect for the way this company handles business is gone. Employees want to be laid off due to the fact that leadership is a laughable group who care only for themselves. It is a sad time for pharma. Over the last 30 years business has become disrespected.
     
  14. anonymous

    anonymous Guest

    We just had a restructuring of the sales force. So there can’t be much more cut there unless the company lets go of a couple of PC drugs which they could do I suppose..Namzaric & Viberzi. They could easily reduce or eliminate most of the Specialty Rep positions. They call on the same people as PC & SR are so much more costly financially to the company.
    They really need to restructure the DMs. I mean like cut them in half. 1 DM could cover 16-20 reps easily. With technology so much can be fine electronically. Field Rides every 4-6 weeks is over kill anyway. You can tell by riding with a rep for 2 days whether they’re doing their job or not. So a ride along once every 3 months is sufficient. Plus more and more offices don’t allow us as DMs to access them with reps anyway.
    Cost cuts will come from reduced spending on commercials, meetings, samples, facilities, etc.
     
  15. anonymous

    anonymous Guest

    I wouldn't take anything off the table as far as cuts go. Facility closures may be on the table as well. I certainly hope that there are no further cuts to R&D. Allergan needs R&D in order to continue to grow. Total S, G & A spend is much higher than R&D spend. When I looked at the financial statements, I was really surprised at how high S, G & A was.
     
  16. anonymous

    anonymous Guest

    What is the most valuable franchise? Restasis. BS has built and nurtured it during his tenure and this should not be expected to change. We will double down to fight Imprimis. The
    Intranasal Tear Neurostimultor is a winner in the dry eye space as well. Restasis has the brand name that commands a premium and always will.
     
  17. anonymous

    anonymous Guest

    Are neurotransmitter sales performing well???
     
  18. anonymous

    anonymous Guest

    "What is the most valuable franchise? Restasis. BS has built and nurtured it during his tenure and this should not be expected to change. We will double down to fight Imprimis. The
    Intranasal Tear Neurostimultor is a winner in the dry eye space as well. Restasis has the brand name that commands a premium and always will."

    Imprimis is not the biggest threat to Restasis by a long shot. Imprimis is a small compound pharmacy. They are trying to ride the coat tails of Restasis news but they can't make Restasis. They can compound Cyclosporine eye drops that aren't commercially available and only then if a doctor specifically requests for a patient based on a medical need (allergic to an ingredient or something). I don't know about you but I have never in my lifetime for me or any family member had a doctor prescribe a drug that required compounding. The market share for compound drugs is small.

    The biggest threat to Restasis is the loss of the patent exclusivity and the entry of other dry eye medications. I agree that Allergan will continue to try and protect the Restasis franchise.
     
  19. anonymous

    anonymous Guest

    Haven’t heard about a neurotransmitter. My friend is Botox neuro and he doesn’t sell it.
     
  20. anonymous

    anonymous Guest

    Viberzi is very important to the company n they will not drop it. it has been doing good n promising